Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan.
Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan.
复制标题
2019年冠状病毒病的特征和结局（COVID-19）患者：日本东京的一项单中心回顾性观察性研究。
DOI：
10.1007/s10147-020-01837-0
复制
发表时间：
2021-03
影响因子：
3.3
通讯作者：
Imamura A
中科院分区：
文献类型：
--
作者：
Nakamura S;Kanemasa Y;Atsuta Y;Fujiwara S;Tanaka M;Fukushima K;Kobayashi T;Shimoyama T;Omuro Y;Sekiya N;Imamura A
尽管严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）已导致2019冠状病毒病（COVID-19）在国际范围内爆发，但有关COVID-19癌症患者临床特征的数据有限。本研究旨在评估日本COVID-19癌症患者的临床特征和结局，包括死亡率和病毒脱落期。我们回顾性分析了2020年1月31日至2020年5月25日期间转诊到我院的32例有癌症病史的患者。我们使用单变量分析评估了临床结果和潜在预后因素之间的关系。中位年龄为74.5岁（范围24-90岁），22例患者（69%）为男性。共有11名患者（34%）死亡。我们的分析表明，死亡率与入院时淋巴细胞计数、白蛋白、乳酸脱氢酶、血清铁蛋白和C反应蛋白显著相关。在幸存者中，发病与首次有效的SARS-CoV-2 PCR阴性结果之间的中位时间为22天（四分位数间距18-25）。在化疗休息期内发生COVID-19的4名血液恶性肿瘤患者中，3名死亡，另一名接受苯达莫司汀加利妥昔单抗治疗的患者病毒脱落持续时间最长（56天）。我们的研究表明，先前在一般COVID-19患者中报告的死亡风险因素，包括淋巴细胞减少症，在癌症患者中也有效。近期接受过细胞毒化疗或接受过化疗（可导致淋巴细胞减少）的患者预后不良，病毒脱落时间延长。本文的在线版本（10.1007/s10147-020-01837-0）包含补充材料，可供授权用户使用。
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an international outbreak of coronavirus disease 2019 (COVID-19), data on the clinical characteristics of COVID-19 patients with cancer are limited. This study aimed to evaluate the clinical characteristics and outcomes including mortality and viral shedding period in COVID-19 patients with cancer in Japan. We retrospectively analyzed 32 patients with a history of cancer who were referred to our hospital between January 31, 2020 and May 25, 2020. We evaluated the association between clinical outcomes and potential prognostic factors using univariate analyses. The median age was 74.5 (range 24–90) years and 22 patients (69%) were men. A total of 11 patients (34%) died. Our analyses demonstrated that the mortality was significantly associated with lymphocyte count, albumin, lactate dehydrogenase, serum ferritin, and C-reactive protein on admission. The median period between illness onset and the first effective negative SARS-CoV-2 PCR result was 22 days (interquartile range 18–25) in survivors. Of four patients with hematological malignancy who developed COVID-19 within the rest period of chemotherapy, three died and the other patient, who received bendamustine plus rituximab therapy, had the longest duration of viral shedding (56 days). Our study suggested that the risk factors for mortality previously reported in general COVID-19 patients, including lymphocytopenia, were also effective in cancer patients. Patients who received cytotoxic chemotherapy recently or were treated with chemotherapy, which can lead to lymphocyte reduction, had poor prognosis and prolonged periods of viral shedding. The online version of this article (10.1007/s10147-020-01837-0) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
82.9
作者：
Robilotti EV;Babady NE;Mead PA;Rolling T;Perez-Johnston R;Bernardes M;Bogler Y;Caldararo M;Figueroa CJ;Glickman MS;Joanow A;Kaltsas A;Lee YJ;Lucca A;Mariano A;Morjaria S;Nawar T;Papanicolaou GA;Predmore J;Redelman-Sidi G;Schmidt E;Seo SK;Sepkowitz K;Shah MK;Wolchok JD;Hohl TM;Taur Y;Kamboj M
通讯作者：
Kamboj M
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
20.3
作者：
Flinn, Ian W.;van der Jagt, Richard;Burke, John M.
通讯作者：
Burke, John M.
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
预测病毒性肺炎患者死亡风险的临床特征：MuLBSTA 评分
影响因子：
5.2
作者：
Guo, Lingxi;Wei, Dong;Qu, Jieming
通讯作者：
Qu, Jieming